Previous 10 | Next 10 |
Ambitious Israel-based biotech Compugen 's (NASDAQ: CGEN) stock had one of the best days in its history Thursday. The shares rose 14% after the company revealed that a deep-pocketed strategic investor will top its list of institutional stockholders. Compugen said that it has str...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Compugen Ltd. Announces Collaboration with Bristol Myers Squibb and $20 Million Equity Investment ” Compugen Ltd. (NASDAQ: CGEN) climbed over 11% in pr...
AZN, BKKT, BKSY, BPTH, CAAS, CASI, OTCQX:CCHWF, CGEN, OTCQX:DTEGF, EMAN, GP, OTCPK:HNHAF, HYZN, ITRM, MIR, MOTS, NGD, NXTD, PX, SOHO, SPB, STRR, OTCPK:TOSBF, VERO, OTCPK:VITFF, VIVO For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earn...
Fossil Group (NASDAQ:FOSL) +32% on Q3 earnings. Babylon (NYSE:BBLN) +28%. Affirm Holdings (NASDAQ:AFRM) +27% on FQ1 earnings. Opendoor Technologies (NASDAQ:OPEN) +18% on Q3 earnings. Society Pass (NASDAQ:SOPA) +19%. ReWalk Robotics (NASDAQ:RWLK) +16% on Q3 earnings. Lordstown Motors...
Compugen (NASDAQ:CGEN) shares are trading ~17.5% higher in the pre-market after announcing that Bristol-Myers Squibb (NYSE:BMY) has completed its $20M in the company. The investment follows the issuance of ~2.3M Compugen shares purchased by Bristol-Myers at ~$8.57 per share, in...
Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment Investment is intended to enhance the strategic collaboration between Compugen and Bristol Myers Squibb and support the continued execution of the clinical programs O...
Compugen to Release Third Quarter 2021 Results on Friday, November 12, 2021 PR Newswire HOLON, Israel , Oct. 26, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, anno...
Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902 - The first patient has been dosed in a Phase 1/2 study of AZD2936, a TIGIT/PD-1 bi-specific derived from COM902, entitling Compugen to receive a $6 m...
Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021 PR Newswire HOLON, Israel , Oct. 1, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy comp...
Compugen to Present at the Cantor Global Healthcare Conference PR Newswire HOLON, Israel , Sept. 14, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...